State Street(R) SPDR(R) S&P(R) Biotech ETF (XBI)

Key Metrics

TER 0.35% per year

Distribution policy Distributing

Fund size USD 10,735 M

Inception date January 31, 2006

Holdings 161

Fund currency USD

Fund domicile US

Provider SPDR

For full official fund details, factsheets, and holdings, visit ssga.com (opens in new tab).

Historical Return

Last updated: Sep 15, 2026

1 Year +68.7% +0.4% Div

3 Years (avg.) +26.9% +0.4% Div

5 Years (avg.) +3.9% +0.4% Div

Risk & Analysis Metrics

Last updated: Sep 15, 2026

Volatility

25.21% 1 Year

26.75% 3 Years

31.58% 5 Years

31.54% 10 Years

Max Drawdown

-10.51% 1 Year

-32.99% 3 Years

-53.18% 5 Years

-63.90% 10 Years

Sharpe Ratio

1.82 1 Year

0.82 3 Years

0.14 5 Years

0.30 10 Years

Return Triangle (Heatmap)

Last updated: Sep 15, 2026

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
2011	3.9%	17.4%	25.3%	29.4%	25.7%	18.3%	21.4%	15.7%	17.2%	20.1%	15.6%	11.1%	11.0%	10.2%	11.6%
2012		32.7%	37.6%	39.2%	31.8%	21.3%	24.6%	17.5%	19.0%	22.0%	16.9%	11.8%	11.6%	10.7%	12.1%
2013			42.7%	42.6%	31.5%	18.7%	23.1%	15.1%	17.2%	20.7%	15.2%	9.9%	9.9%	9.0%	10.7%
2014				42.5%	26.2%	11.6%	18.6%	10.2%	13.4%	17.9%	12.2%	6.8%	7.1%	6.4%	8.4%
2015					11.8%	-1.2%	11.6%	3.4%	8.3%	14.2%	8.4%	3.0%	3.7%	3.3%	5.7%
2016						-12.7%	11.5%	0.7%	7.5%	14.7%	7.9%	1.8%	2.7%	2.4%	5.1%
2017							42.4%	8.2%	15.2%	22.8%	12.6%	4.5%	5.2%	4.5%	7.3%
2018								-17.7%	3.6%	16.9%	6.1%	-1.8%	0.0%	0.0%	3.6%
2019									30.5%	39.3%	15.5%	2.6%	4.0%	3.3%	7.1%
2020										48.7%	8.7%	-5.3%	-1.8%	-1.5%	3.6%
2021											-20.6%	-24.4%	-14.5%	-11.1%	-3.6%
2022												-28.1%	-11.3%	-7.7%	1.2%
2023													9.5%	4.6%	13.3%
2024														-0.2%	15.3%
2025															33.2%

Distributions

*by ETF Portfolio Weight Last updated: Sep 15, 2026

Profit Margin Distribution

< 0%

68%

1y 3y N/A N/A

0 - 5%

1y 3y N/A N/A

5 - 10%

1y 3y N/A N/A

10 - 15%

1y 3y N/A N/A

15 - 20%

1y 3y N/A N/A

20 - 30%

1y 3y N/A N/A

30 - 40%

1y 3y N/A N/A

> 40%

1y 3y N/A N/A

P/E Ratio Distribution

< 0

78%

1y 3y N/A N/A

0 - 10

1y 3y N/A N/A

10 - 15

1y 3y N/A N/A

15 - 20

1y 3y N/A N/A

20 - 25

1y 3y N/A N/A

25 - 35

1y 3y N/A N/A

35 - 50

1y 3y N/A N/A

> 50

1y 3y N/A N/A

Discounted Cash Flow

Weighted Average Undervaluation

N/A

Undervalued

> 60%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

15 - 30%

1y 3y N/A N/A

Fair (±15%)

1y 3y N/A N/A

Overvalued

15 - 30%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

> 60%

1y 3y N/A N/A

Market Cap Size Distribution

Micro Cap

2.4%

1y 3y N/A N/A

Small Cap

20.7%

1y 3y N/A N/A

Mid Cap

51.6%

1y 3y N/A N/A

Large Cap

23.2%

1y 3y N/A N/A

Mega Cap

2.1%

1y 3y N/A N/A

Micro: < $300M Small: $300M–$2B Mid: $2B–$10B Large: $10B–$200B Mega: > $200B

Average metrics of all companies in portfolio

Last updated: Sep 20, 2026

Market
Average

Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares.	$30.9B	-
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price.	0.22%	2.02%
Beta Indicates the relationship between the price performance of a share and the market.	0.83	-
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth.	34.02	23.0
Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything	-31.45	-
Profitable Companies	41%	-
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued.	75.89	18.54
Price to Sales Ratio Market cap divided by the revenue in the most recent year.	14.47	9.29
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company	15.43	11.99

Market
Average

Enterprise Value to EBIT Enterprise Value divided by EBIT	-5.88	11.72
Enterprise Value to Revenue Enterprise value divided by revenue	522.39	12.55
Total Debt to Enterprise Value Total debt divided by enterprise value	0.08	0.04
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary.	-	0.32
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability.	-10318.06%	21.55%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago.	-	+54.6%
Return on Equity Equity divided by market cap.	-34.32%	1.97%
Return on Assets Indicates a company's profitability in relation to its total assets.	6.48%	4.03%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits.	-75.09%	3.69%

Sectors

Manufacturing	64.5%
Professional, Scientific, and Technical Services	17.7%
Health Care and Social Assistance	4.1%
Healthcare	2.9%
Basic Materials	0.5%
Other	10.4%

Countries

United States	95.2%
United Kingdom	1.4%
Ireland	1.1%
Netherlands	1.0%
Switzerland	1.0%
Other	0.2%

Limit holdings to companies in a single sector.

$0B >$1T

Ratio between share price and earnings per share. A low ratio could indicate undervaluation.

<0 >50

Ratio of dividends in the last 12 months to current share price.

0% 3%

Revenue increase compared to the same quarter one year ago.

0% 30%

Net income increase compared to the same quarter one year ago.

0% 30%

Profitability of the last quarter.

<-30% >30%

A higher ratio indicates a higher risk. The ratio is difficult to compare between industries.

<0 >3

Discounted cash flow valuation vs. current price. Positive = undervalued, negative = overvalued.

<-50% >+100%

Market Cap

P/E Ratio

Total Investment

Weight

Apogee Therapeutics Inc.

APGE

Market Cap $8.36B

P/E Ratio -31.1

Dividends 0.0%

Total Investment $159.76M

Weight 1.49%

Loading details…

Moderna Inc

MRNA - Manufacturing

Market Cap $61.12B

P/E Ratio -19.3

Dividends 0.0%

Total Investment $151.61M

Weight 1.41%

Loading details…

Twist Bioscience Corp

TWST - Professional, Scientific, and Technical Services

Market Cap $10.4B

P/E Ratio -75.2

Dividends 0.0%

Total Investment $151.14M

Weight 1.41%

Loading details…

ARCA biopharma Inc

ABIO - Healthcare

Market Cap $5.73B

P/E Ratio -38.4

Dividends 0.0%

Total Investment $147.99M

Weight 1.38%

Loading details…

Kymera Therapeutics Inc

KYMR - Manufacturing

Market Cap $9.69B

P/E Ratio -36.2

Dividends 0.0%

Total Investment $145.95M

Weight 1.36%

Loading details…

Viking Therapeutics Inc

VKTX - Manufacturing

Market Cap $3.38B

P/E Ratio -6.2

Dividends 0.0%

Total Investment $139.97M

Weight 1.30%

Loading details…

Praxis Precision Medicines Inc

PRAX - Manufacturing

Market Cap $8.33B

P/E Ratio -23.1

Dividends 0.0%

Total Investment $138.52M

Weight 1.29%

Loading details…

Erasca Inc

ERAS - Professional, Scientific, and Technical Services

Market Cap $5.13B

P/E Ratio -15.5

Dividends 0.0%

Total Investment $136.43M

Weight 1.27%

Loading details…

Revolution Medicines Inc

RVMD - Manufacturing

Market Cap $40.6B

P/E Ratio -21.6

Dividends 0.0%

Total Investment $129.32M

Weight 1.20%

Loading details…

Rhythm Pharmaceuticals Inc.

RYTM - Manufacturing

Market Cap $6.7B

P/E Ratio -31.4

Dividends 0.0%

Total Investment $128.98M

Weight 1.20%

Loading details…

SELLAS Life Sciences Group Inc

SLS - Manufacturing

Market Cap $2.14B

P/E Ratio -54.4

Dividends 0.0%

Total Investment $127.74M

Weight 1.19%

Loading details…

Vaxcyte Inc

PCVX - Manufacturing

Market Cap $8.39B

P/E Ratio -7.6

Dividends 0.0%

Total Investment $127.43M

Weight 1.19%

Loading details…

Magenta Therapeutics Inc

MGTA - Professional, Scientific, and Technical Services

Market Cap $42.44M

P/E Ratio -0.0

Dividends 0.0%

Total Investment $127.01M

Weight 1.18%

Loading details…

Cytokinetics Inc

CYTK - Manufacturing

Market Cap $8.56B

P/E Ratio -9.5

Dividends 0.0%

Total Investment $126.46M

Weight 1.18%

Loading details…

Natera Inc

NTRA - Health Care and Social Assistance

Market Cap $52.9B

P/E Ratio -271.6

Dividends 0.0%

Total Investment $124.85M

Weight 1.16%

Loading details…

Scholar Rock Holding Corp

SRRK - Professional, Scientific, and Technical Services

Market Cap $5.59B

P/E Ratio -14.1

Dividends 0.0%

Total Investment $124.2M

Weight 1.16%

Loading details…

Roivant Sciences Ltd

ROIV

Market Cap $28.73B

P/E Ratio -104.7

Dividends 0.0%

Total Investment $124.03M

Weight 1.16%

Loading details…

Mirum Pharmaceuticals Inc

MIRM - Professional, Scientific, and Technical Services

Market Cap $5.6B

P/E Ratio -6.3

Dividends 0.0%

Total Investment $124M

Weight 1.16%

Loading details…

Cogent Biosciences Inc

COGT - Manufacturing

Market Cap $5.38B

P/E Ratio -13.6

Dividends 0.0%

Total Investment $122.79M

Weight 1.14%

Loading details…

Ultragenyx Pharmaceutical Inc.

RARE - Manufacturing

Market Cap $1.43B

P/E Ratio -2.5

Dividends 0.0%

Total Investment $122.44M

Weight 1.14%

Loading details…

Key Metrics

Compare similar ETFs

Historical Return

Risk & Analysis Metrics

Volatility

Max Drawdown

Sharpe Ratio

Return Triangle (Heatmap)

Distributions

Profit Margin Distribution

P/E Ratio Distribution

Discounted Cash Flow

Market Cap Size Distribution

Portfolio Concentration

Latest News

Moderna's Comeback Is Finally Taking Shape -- and There May Be More Upside Ahead

Moderna's personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped

Moderna Is Up 350% Since Our Recommendation. Here's What to Do Next.

Average metrics of all companies in portfolio

Sectors

Countries

Stock Screener

Apogee Therapeutics Inc.

Apogee Therapeutics Inc.

Moderna Inc

Moderna Inc

Twist Bioscience Corp

Twist Bioscience Corp

ARCA biopharma Inc

ARCA biopharma Inc

Kymera Therapeutics Inc

Kymera Therapeutics Inc

Viking Therapeutics Inc

Viking Therapeutics Inc

Praxis Precision Medicines Inc

Praxis Precision Medicines Inc

Erasca Inc

Erasca Inc

Revolution Medicines Inc

Revolution Medicines Inc

Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences Group Inc

Vaxcyte Inc

Vaxcyte Inc

Magenta Therapeutics Inc

Magenta Therapeutics Inc

Cytokinetics Inc

Cytokinetics Inc

Natera Inc

Natera Inc

Scholar Rock Holding Corp

Scholar Rock Holding Corp

Roivant Sciences Ltd

Roivant Sciences Ltd

Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Inc

Cogent Biosciences Inc

Cogent Biosciences Inc

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc.

Cookie Settings